CD274 and non-small cell lung carcinoma: NCT03088540 trials reported that cemiplimab improves overall survival and progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer with PD-L1 of at least 50%, providing a potential new treatment option for these patients [232].